Response to ultrasound-guided greater occipital nerve block in people with medication-overuse headache.

Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade

Sultan 1. Murat State Hospital · NCT07487649

This project tries to see if patient factors predict how adults with medication-overuse headache respond to an ultrasound-guided greater occipital nerve block.

Quick facts

Study typeObservational
Enrollment70 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorSultan 1. Murat State Hospital (other gov)
Locations1 site (Edirne)
Trial IDNCT07487649 on ClinicalTrials.gov

What this trial studies

This is a single-center observational study of adults aged 18–65 with medication-overuse headache related to triptans or NSAIDs who previously had chronic migraine or chronic tension-type headache. Researchers record patient-related factors before an ultrasound-guided greater occipital nerve block and then track treatment outcomes afterward. No randomization or experimental drug is involved; the study analyzes which baseline features are linked to better or worse response. The work is conducted at Sultan 1. Murat State Hospital in Edirne with standard clinical follow-up measures.

Who should consider this trial

Good fit: Adults 18 to 65 with medication-overuse headache per ICHD-3 tied to triptan or NSAID use and a prior diagnosis of chronic migraine or chronic tension-type headache are ideal candidates.

Not a fit: People who are pregnant or breastfeeding, have severe psychiatric or other neurological disorders, secondary headache, recent severe head/neck trauma, substance abuse, or significant systemic disease are excluded and unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, clinicians could better predict which patients with medication-overuse headache are likely to benefit from a greater occipital nerve block and personalize care.

How similar studies have performed: Previous studies of occipital nerve blocks in chronic headache populations have shown mixed but generally promising results, so this approach is not entirely novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 18 and 65 years
* Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)
* Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs
* Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria

Exclusion Criteria:

* History of severe head or neck trauma or previous neurosurgical intervention
* Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)
* History of infectious disease, chronic inflammatory disease, or malignancy
* Previous diagnosis of secondary headache
* History of substance abuse
* Pregnancy or breastfeeding
* History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)
* Difficulty with cooperation
* Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)

Where this trial is running

Edirne

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Medication-overuse Headache, Treatment, Headache, Greater Occipital Nerve Block

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.